Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses

SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses

(2023) Ashley M. Burton et al.   CELLULAR IMMUNOLOGY

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

(2023) Yungan TAO et al.   EUROPEAN JOURNAL OF CANCER

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

(2023) Melissa L Johnson et al.   ONCOLOGIST

A phase I study of LCL161, a novel oral pan‐inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

(2022) Sachi Morita et al.   Asia-Pacific Journal of Clinical Oncology

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design

(2022) Jean Bourhis et al.   Future Oncology

Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer

(2021) Carlos Gomez‐Roca et al.   CTS-Clinical and Translational Science

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

(2021) Naveen Pemmaraju et al.   Blood Advances

The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy

(2020) Jessica Michie et al.   Cells

Targeting XIAP for Promoting Cancer Cell Death—The Story of ARTS and SMAC

(2020) Ruqaia Abbas et al.   Cells

Potency and Selectivity of SMAC/DIABLO Mimetics in Solid Tumor Therapy

(2020) Xiao-Yun Zhao et al.   Cells

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

(2020) Xu-Shan Sun et al.   LANCET ONCOLOGY

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

(2018) Zhen Tao et al.   CLINICAL CANCER RESEARCH

DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death

(2018) Benoît Thibault et al.   Scientific Reports

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

(2015) R. K. Amaravadi et al.   MOLECULAR CANCER THERAPEUTICS

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma

(2015) Oscar Matzinger et al.   RADIOTHERAPY AND ONCOLOGY

Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors

(2014) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulation of immune signalling by inhibitors of apoptosis

(2012) Shawn T. Beug et al.   TRENDS IN IMMUNOLOGY

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

(2011) Qian Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY